In lung cancer, non-small cell lung cancer (NSCLC) cells are often intrinsically resistant to certain anticancer drugs, whereas small cell lung cancer (SCLC) cells can acquire resistance with continued administration of the drug. Cancer cells are intrinsically resistant to anti-cancer agents because of genetic and epigenetic heterogeneity. These cells also acquire resistance to a wide variety of chemotherapeutic drugs through alteration in absorption, metabolism and excretion of a drug. Strategies also quite often initiate cancer cells to evade cell death by expressing mechanisms of resistance known as MDR that can result from changes that limit accumulation of drugs within cells by limiting uptake, enhancing efflux, or affecting membrane lipids.
The top journals are peer reviewed scholarly journals. These provide high quality, meticulously reviewed and rapid publication, to cater the insistent need of scientific community. These journals are indexed with all their citations noted. The top open access journals are indexed in MEDLINE, PUBMED, SCOPUS, COPERNICUS, CAS, EBSCO and ISI.
Last date updated on July, 2020